Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.34
OFIX's Cash to Debt is ranked higher than
63% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. OFIX: 1.34 )
OFIX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 1.34

Equity to Asset 0.76
OFIX's Equity to Asset is ranked higher than
82% of the 373 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. OFIX: 0.76 )
OFIX' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.85
Current: 0.76

0.36
0.85
F-Score: 4
Z-Score: 5.38
M-Score: -3.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1.27
OFIX's Operating margin (%) is ranked higher than
60% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. OFIX: -1.27 )
OFIX' s 10-Year Operating margin (%) Range
Min: -49.44   Max: 24.18
Current: -1.27

-49.44
24.18
Net-margin (%) -6.37
OFIX's Net-margin (%) is ranked higher than
58% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. OFIX: -6.37 )
OFIX' s 10-Year Net-margin (%) Range
Min: -43.98   Max: 34.01
Current: -6.37

-43.98
34.01
ROE (%) -8.22
OFIX's ROE (%) is ranked higher than
58% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 5.57 vs. OFIX: -8.22 )
OFIX' s 10-Year ROE (%) Range
Min: -113.11   Max: 33.7
Current: -8.22

-113.11
33.7
ROA (%) -6.03
OFIX's ROA (%) is ranked higher than
58% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. OFIX: -6.03 )
OFIX' s 10-Year ROA (%) Range
Min: -40.72   Max: 23.53
Current: -6.03

-40.72
23.53
ROC (Joel Greenblatt) (%) -2.14
OFIX's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 12.89 vs. OFIX: -2.14 )
OFIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -115.25   Max: 59.91
Current: -2.14

-115.25
59.91
Revenue Growth (%) -12.10
OFIX's Revenue Growth (%) is ranked higher than
52% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. OFIX: -12.10 )
OFIX' s 10-Year Revenue Growth (%) Range
Min: -12.1   Max: 18.5
Current: -12.1

-12.1
18.5
EBITDA Growth (%) -46.80
OFIX's EBITDA Growth (%) is ranked higher than
51% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -2.90 vs. OFIX: -46.80 )
OFIX' s 10-Year EBITDA Growth (%) Range
Min: -46.8   Max: 60.2
Current: -46.8

-46.8
60.2
» OFIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

OFIX Guru Trades in Q3 2013

Arnold Schneider 141,068 sh (+588.67%)
Richard Snow 103,815 sh (+130.52%)
Jim Simons 92,179 sh (+128.85%)
Diamond Hill Capital 751,286 sh (+10.11%)
Mario Gabelli 93,625 sh (+7.15%)
Joel Greenblatt Sold Out
David Dreman Sold Out
» More
Q4 2013

OFIX Guru Trades in Q4 2013

Jim Simons 179,179 sh (+94.38%)
Mario Gabelli 98,325 sh (+5.02%)
Richard Snow 94,045 sh (-9.41%)
Arnold Schneider 112,857 sh (-20%)
Diamond Hill Capital 372,646 sh (-50.4%)
» More
Q1 2014

OFIX Guru Trades in Q1 2014

Joel Greenblatt 26,468 sh (New)
Paul Tudor Jones 8,329 sh (New)
Chuck Royce 60,000 sh (New)
Arnold Schneider 119,993 sh (+6.32%)
Diamond Hill Capital 391,926 sh (+5.17%)
Mario Gabelli 99,725 sh (+1.42%)
Richard Snow Sold Out
Jim Simons 36,379 sh (-79.7%)
» More
Q2 2014

OFIX Guru Trades in Q2 2014

Jim Simons 113,769 sh (+212.73%)
Diamond Hill Capital 454,236 sh (+15.9%)
Paul Tudor Jones 9,324 sh (+11.95%)
Joel Greenblatt Sold Out
Chuck Royce 59,300 sh (-1.17%)
Mario Gabelli 98,125 sh (-1.6%)
Arnold Schneider 111,938 sh (-6.71%)
» More
» Details

Insider Trades

Latest Guru Trades with OFIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Sold Out 0.01%$29.68 - $35.8 $ 33.143%0
Joel Greenblatt 2014-03-31 New Buy0.01%$20.5 - $30.38 $ 33.1444%26468
David Dreman 2013-09-30 Sold Out 0.17%$21.55 - $28.58 $ 33.1436%0
Joel Greenblatt 2013-09-30 Sold Out 0.14%$21.55 - $28.58 $ 33.1436%0
Joel Greenblatt 2013-06-30 New Buy0.14%$26.19 - $35.76 $ 33.1411%125677
David Dreman 2013-03-31 New Buy0.29%$35.87 - $39.94 $ 33.14-12%305324
Joel Greenblatt 2012-12-31 Sold Out 0.16%$36.47 - $45.52 $ 33.14-16%0
Joel Greenblatt 2012-09-30 New Buy0.16%$40.25 - $44.9 $ 33.14-21%53003
Joel Greenblatt 2012-03-31 Sold Out 0.09%$34.28 - $42.92 $ 33.14-11%0
Joel Greenblatt 2011-12-31 Add 174.1%0.06%$30.84 - $36.03 $ 33.14-1%21048
Joel Greenblatt 2011-09-30 Reduce -37.89%0.03%$33.61 - $44.52 $ 33.14-14%7679
Joel Greenblatt 2011-06-30 Reduce -46.81%0.11%$32.92 - $42.22 $ 33.14-11%12364
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.90
OFIX's P/B is ranked higher than
78% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. OFIX: 1.90 )
OFIX' s 10-Year P/B Range
Min: 0.77   Max: 3.17
Current: 1.9

0.77
3.17
P/S 1.53
OFIX's P/S is ranked higher than
78% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 3.21 vs. OFIX: 1.53 )
OFIX' s 10-Year P/S Range
Min: 0.31   Max: 3.87
Current: 1.53

0.31
3.87
PFCF 43.61
OFIX's PFCF is ranked higher than
77% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. OFIX: 43.61 )
OFIX' s 10-Year PFCF Range
Min: 6.45   Max: 535.73
Current: 43.61

6.45
535.73
EV-to-EBIT -56.48
OFIX's EV-to-EBIT is ranked lower than
55% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 57.01 vs. OFIX: -56.48 )
OFIX' s 10-Year EV-to-EBIT Range
Min: 7.1   Max: 128.1
Current: -56.48

7.1
128.1
Current Ratio 5.02
OFIX's Current Ratio is ranked higher than
86% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. OFIX: 5.02 )
OFIX' s 10-Year Current Ratio Range
Min: 1.56   Max: 5.15
Current: 5.02

1.56
5.15
Quick Ratio 3.35
OFIX's Quick Ratio is ranked higher than
82% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. OFIX: 3.35 )
OFIX' s 10-Year Quick Ratio Range
Min: 1.13   Max: 4.2
Current: 3.35

1.13
4.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 20.46
OFIX's Price/Net Current Asset Value is ranked higher than
84% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. OFIX: 20.46 )
OFIX' s 10-Year Price/Net Current Asset Value Range
Min: 6.14   Max: 715.65
Current: 20.46

6.14
715.65
Price/Tangible Book 2.36
OFIX's Price/Tangible Book is ranked higher than
84% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 6.09 vs. OFIX: 2.36 )
OFIX' s 10-Year Price/Tangible Book Range
Min: 1.48   Max: 104.21
Current: 2.36

1.48
104.21
Price/DCF (Projected) 1.47
OFIX's Price/DCF (Projected) is ranked higher than
91% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. OFIX: 1.47 )
OFIX' s 10-Year Price/DCF (Projected) Range
Min: 0.55   Max: 3.44
Current: 1.47

0.55
3.44
Price/Median PS Value 1.09
OFIX's Price/Median PS Value is ranked higher than
73% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 1.15 vs. OFIX: 1.09 )
OFIX' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 3.3
Current: 1.09

0.36
3.3
Earnings Yield (Greenblatt) 4.60
OFIX's Earnings Yield (Greenblatt) is ranked higher than
69% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. OFIX: 4.60 )
OFIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 14.1
Current: 4.6

0.8
14.1
Forward Rate of Return (Yacktman) 3.36
OFIX's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. OFIX: 3.36 )
OFIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.5   Max: 35.8
Current: 3.36

2.5
35.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:OFX.Germany
Orthofix International N.V., is a limited liability company operating under the laws of Curacao. The company is a global medical device company focused on developing and delivering innovative repair and regenerative solutions to the spine and orthopedic markets. Its products are designed to address the lifelong bone-and-joint health needs of patients of all ages, helping them achieve a more active and mobile lifestyle. The Company designs, develops, manufactures, markets and distributes medical equipment used mainly by musculoskeletal medical specialists for spine and orthopedic applications. Its main products are spinal implant products and related human cellular and tissue based products ('HCT/P products') used in surgical procedures, non-invasive regenerative stimulation products used to enhance bone growth and the success rate of spinal fusions and to treat non-union fractures, external and internal fixation devices used in fracture repair, limb lengthening and bone reconstruction. Its products also include bone cement and devices for removal of bone cement used to fix artificial implants. The Company manages its business by its two global business units ('GBUs'), which are comprised of Spine and Orthopedics supported by corporate activities. Spine provides a portfolio of repair and regenerative products that allow physicians to successfully treat a variety of spinal conditions. This global business unit specializes in the design, development and marketing of the Company's spinal repair products along with regenerative stimulation and biologics products used in spine applications. Spine distributes its products through a network of distributors, sales representatives and affiliates. This global business unit uses both direct and distributor sales representatives to sell spine products to hospitals, doctors and other healthcare providers, globally. Orthopedics provides a portfolio of repair and regenerative products that allow physicians to successfully treat a variety of orthopedic conditions unrelated to spine. This global business unit specializes in the design, development and marketing of the Company's orthopedic repair products along with regeneration stimulation and biologics products used in orthopedic applications. Orthopedics distributes its products through a network of distributors, sales representatives and affiliates. This global business unit uses both direct and distributor sales representatives to sell orthopedics products to hospitals, doctors and other healthcare providers, globally. Its regenerative stimulation products compete mainly with similar products marketed by Biomet Spine, a business unit of Biomet, Inc; DJO Incorporated; and the Exogen product line owned by Smith and Nephew plc. and Essex Woodland, a private equity firm. Its spinal implant, HCT/P products, and Trinity Evolution , an HCT/P product from which it derives marketing fees, competes with products marketed by Medtronic, Inc.; De Puy Synth
» More Articles for NAS:OFIX

Headlines

Articles On GuruFocus.com
Three Growing Companies Worth a Second Look Oct 09 2013 
Weekly CEO Buys Highlight: MOSY, PMT, APA, CUBI, OFIX May 26 2013 
Weekly 3-Year Low Highlights: SBY, PER, OFIX, EDG May 14 2013 
Orthofix International N.V. Reports Operating Results (10-K) Mar 03 2011 
Orthofix International N.V. (OFIX) CEO Alan Milinazzo buys 1,100 Shares Nov 09 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Oct 28 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Jul 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Apr 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Nov 06 2009 
Orthofix International Announces Record Revenue in 2nd Quarter 2009 Jul 30 2009 

More From Other Websites
Orthofix Updates Filing Status Aug 19, 2014 Aug 20 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Entry into a Material Definitive Agreement, Notice of... Aug 19 2014
[$$] Orthofix to Restate Results Aug 19 2014
Orthofix Updates Filing Status Aug 19 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2014
Orthofix Announces Delay of Form 10-Q Filing and Provides Preliminary Second Quarter 2014 Net Sales... Aug 06 2014
[$$] Orthofix Delays Earnings Release Aug 06 2014
Orthofix Announces Delay of Form 10-Q Filing and Provides Preliminary Second Quarter 2014 Net Sales... Aug 06 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 19 2014
U.S. Companies Catch World Cup Fever with Foreign Mergers Jun 16 2014
Orthofix International to Participate in the Jefferies 2014 Global Healthcare Conference May 29 2014
ORTHOFIX INTERNATIONAL N V Financials May 16 2014
Orthofix management to meet with JMP Securities May 12 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... May 08 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 10-Q, Quarterly Report May 08 2014
Orthofix International Reports First Quarter 2014 Results May 07 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2014
Mark A. Heggestad Joins Orthofix as New Chief Financial Officer May 05 2014
Orthofix International Announces First Quarter 2014 Earnings Conference Call Apr 30 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Apr 25 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK